gp(33 41)

GP(33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus and can upregulate H-2Db molecules at the RMA-S (Db Kb) cell surface with an SC50 of 344 nM. GP33-41 Epitope is a strong agonist of CD8 T cells.

LCMV gp33-41 (TFA), the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes[1].

LCMV gp33-41, the carboxyl-extended 11-aa-long peptide, is a sequence of lymphocytic choriomeningitis virus restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes. This is the H-2Db restricted epitope derived from the lymphocytic.

GP(33-41) TFA 是一种由 9 个氨基酸残基组成的多肽，它是淋巴细胞性脉络丛脑膜炎病毒 GP1 抗原决定基中的序列。GP(33-41) TFA 能够上调 RMA-S (Db Kb) 细胞表面 H-2Db 分子，SC50值为 344 nM。

LCMV gp33-41 (TFA)是一种带有羧基延伸的11-aa长肽，作为淋巴细胞脉络丛脑膜炎病毒序列，在MHC I类H-2Db分子的限制下，能够被呈递给细胞毒性T淋巴细胞。

LCMV gp33-41 acetate 是淋巴细胞性脉络丛脑膜炎病毒的序列，受主要组织相容性复合体 I 类 H-2Db 限制，呈递给细胞毒性 T 淋巴细胞。